| Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
|---|
| Acrivastine | hsa00030 | Pentose phosphate pathway | 1.69E-02 | 2 | P60891, P37837 | PRPS1, TALDO1 | More | | | Acrivastine | hsa00190 | Oxidative phosphorylation | 1.54E-03 | 3 | Q16718, Q13488, O14521 | NDUFA5, TCIRG1, SDHD | More | | | Acrivastine | hsa00240 | Pyrimidine metabolism | 8.44E-04 | 4 | P31350, P21589, P32320, P04183 | RRM2, NT5E, CDA, TK1 | More | | | Acrivastine | hsa00524 | Neomycin, kanamycin and gentamicin biosynthesis | 2.03E-02 | 1 | P35557 | GCK | More | | | Acrivastine | hsa00590 | Arachidonic acid metabolism | 3.85E-02 | 2 | P11712, P09960 | CYP2C9, LTA4H | More | | | Acrivastine | hsa00591 | Linoleic acid metabolism | 1.29E-03 | 1 | P11712 | CYP2C9 | More | | | Acrivastine | hsa00630 | Glyoxylate and dicarboxylate metabolism | 4.29E-03 | 2 | P40925, P15104 | MDH1, GLUL | More | | | Acrivastine | hsa00730 | Thiamine metabolism | 1.15E-03 | 2 | Q9Y6K8, P24666 | AK5, ACP1 | More | | | Acrivastine | hsa00740 | Riboflavin metabolism | 4.03E-02 | 1 | P24666 | ACP1 | More | | | Acrivastine | hsa00770 | Pantothenate and CoA biosynthesis | 1.15E-02 | 2 | O95498, Q9NRN7 | VNN2, AASDHPPT | More | | | Acrivastine | hsa00860 | Porphyrin and chlorophyll metabolism | 1.69E-02 | 2 | P36551, P30043 | CPOX, BLVRB | More | | | Acrivastine | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 9.14E-03 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | | Acrivastine | hsa00982 | Drug metabolism - cytochrome P450 | 9.14E-03 | 2 | P11712, P78417 | CYP2C9, GSTO1 | More | | | Acrivastine | hsa00983 | Drug metabolism - other enzymes | 4.84E-05 | 4 | P04183, P32320, P31350, P05164 | TK1, CDA, RRM2, MPO | More | | | Acrivastine | hsa01230 | Biosynthesis of amino acids | 3.59E-02 | 3 | P60891, Q99707, P37837 | PRPS1, MTR, TALDO1 | More | | | Acrivastine | hsa01240 | Biosynthesis of cofactors | 2.52E-02 | 2 | Q9BQB6, P14550 | VKORC1, AKR1A1 | More | | | Acrivastine | hsa01522 | Endocrine resistance | 4.74E-02 | 3 | P22694, P10415, Q13323 | PRKACB, BCL2, BIK | More | | | Acrivastine | hsa02010 | ABC transporters | 2.29E-02 | 2 | P45844, P08183 | ABCG1, ABCB1 | More | | | Acrivastine | hsa03008 | Ribosome biogenesis in eukaryotes | 1.88E-02 | 3 | O14980, O60832, Q9BVP2 | XPO1, DKC1, GNL3 | More | | | Acrivastine | hsa03013 | RNA transport | 2.35E-05 | 10 | O14980, P52298, O14893, P61326, Q7Z3B4, P35658, Q14152, Q14240, P23588, Q9Y6A5 | XPO1, NCBP2, GEMIN2, MAGOH, NUP54, NUP214, EIF3A, EIF4A2, EIF4B, TACC3 | More | | | Acrivastine | hsa03022 | Basal transcription factors | 3.32E-02 | 2 | O00268, Q15544 | TAF4, TAF11 | More | | | Acrivastine | hsa03040 | Spliceosome | 6.28E-03 | 6 | Q14562, O43143, O60508, Q07955, Q01130, Q13243 | DHX8, DHX15, CDC40, SFRS1, SFRS2, SFRS5 | More | | | Acrivastine | hsa03050 | Proteasome | 4.83E-02 | 1 | P55036 | PSMD4 | More | | | Acrivastine | hsa03410 | Base excision repair | 2.52E-02 | 2 | P49005, P29372 | POLD2, MPG | More | | | Acrivastine | hsa04024 | cAMP signaling pathway | 4.38E-02 | 4 | P42338, P0DP23, Q13370, Q13009 | PIK3CB, CALM1, PDE3B, TIAM1 | More | | | Acrivastine | hsa04060 | Cytokine-cytokine receptor interaction | 2.61E-02 | 10 | P27930, P08476, P25024, P25025, Q9UBD3, P47992, P01375, P09341, P18510, Q93038 | IL1R2, INHBA, CXCR1, CXCR2, XCL2, XCL1, TNF, CXCL1, IL1RN, TNFRSF25 | More | | | Acrivastine | hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 2.33E-03 | 8 | P09341, P19875, P25024, P25025, P47992, Q9UBD3, P14784, P01375 | CXCL1, CXCL2, CXCR1, CXCR2, XCL1, XCL2, IL2RB, TNF | More | | | Acrivastine | hsa04062 | Chemokine signaling pathway | 1.83E-02 | 8 | P25024, P25025, P09341, P19875, P42338, P19174, P63218, P50151 | CXCR1, CXCR2, CXCL1, CXCL2, PIK3CB, PLCG1, GNG5, GNG10 | More | | | Acrivastine | hsa04064 | NF-kappa B signaling pathway | 1.87E-04 | 12 | P10415, P51617, P14778, P19174, Q04759, Q9UDY8, P06239, Q13315, P24522, P09341, P19875, Q06643 | BCL2, IRAK1, IL1R1, PLCG1, PRKCQ, MALT1, LCK, ATM, GADD45A, CXCL1, CXCL2, LTB | More | | | Acrivastine | hsa04070 | Phosphatidylinositol signaling system | 3.21E-03 | 5 | P0DP23, P42338, Q86XP1, P27987, Q96DU7 | CALM1, PIK3CB, DGKH, ITPKB, ITPKC | More | | | Acrivastine | hsa04072 | Phospholipase D signaling pathway | 4.48E-02 | 5 | P42338, P43657, P25024, P25025, P19174 | PIK3CB, P2RY5, CXCR1, CXCR2, PLCG1 | More | | | Acrivastine | hsa04080 | Neuroactive ligand-receptor interaction | 4.80E-04 | 8 | P08311, Q15722, P21453, Q9H228, O00398, P21462, P21730, P07550 | CTSG, LTB4R, S1PR1, EDG8, P2RY10, FPR1, C5AR1, ADRB2 | More | | | Acrivastine | hsa04114 | Oocyte meiosis | 1.33E-02 | 4 | P51812, Q02750, P16298, Q17RY0 | RPS6KA3, MAP2K1, PPP3CB, CPEB4 | More | | | Acrivastine | hsa04115 | p53 signaling pathway | 3.35E-03 | 5 | P24522, Q13315, P31350, O95067, P10415 | GADD45A, ATM, RRM2, CCNB2, BCL2 | More | | | Acrivastine | hsa04120 | Ubiquitin mediated proteolysis | 3.44E-02 | 4 | Q14145, Q13042, P62837, Q15751 | KEAP1, CDC16, UBE2D2, HERC1 | More | | | Acrivastine | hsa04136 | Autophagy - other | 5.92E-03 | 2 | O94817, Q9H1Y0 | ATG12, ATG5 | More | | | Acrivastine | hsa04140 | Autophagy - animal | 4.74E-02 | 3 | P22694, Q14643, P10415 | PRKACB, ITPR1, BCL2 | More | | | Acrivastine | hsa04145 | Phagosome | 1.42E-04 | 9 | Q15080, P14598, P68371, Q13488, P05164, P78380, O60603, P35443, P13765 | NCF4, NCF1, TUBB2C, TCIRG1, MPO, OLR1, TLR2, THBS4, HLA-DOB | More | | | Acrivastine | hsa04150 | mTOR signaling pathway | 3.60E-02 | 3 | Q02750, Q9NQL2, P51812 | MAP2K1, RRAGD, RPS6KA3 | More | | | Acrivastine | hsa04213 | Longevity regulating pathway - multiple species | 3.85E-02 | 4 | P42338, Q9Y4H2, P11142, Q13547 | PIK3CB, IRS2, HSPA8, HDAC1 | More | | | Acrivastine | hsa04217 | Necroptosis | 2.34E-02 | 4 | P01375, P48023, Q14765, Q99878 | TNF, FASLG, STAT4, H2AC14 | More | | | Acrivastine | hsa04340 | Hedgehog signaling pathway | 9.74E-03 | 3 | P22694, Q13635, P10415 | PRKACB, PTCH1, BCL2 | More | | | Acrivastine | hsa04360 | Axon guidance | 1.71E-02 | 4 | P20827, O95631, P42338, P23528 | EFNA1, NTN1, PIK3CB, CFL1 | More | | | Acrivastine | hsa04370 | VEGF signaling pathway | 2.68E-03 | 3 | P16298, Q05397, Q02750 | PPP3CB, PTK2, MAP2K1 | More | | | Acrivastine | hsa04530 | Tight junction | 3.29E-02 | 3 | P16989, P56750, Q14247 | CSDA, CLDN17, CTTN | More | | | Acrivastine | hsa04540 | Gap junction | 2.86E-02 | 3 | P22694, P68371, Q14643 | PRKACB, TUBB2C, ITPR1 | More | | | Acrivastine | hsa04610 | Complement and coagulation cascades | 2.78E-03 | 1 | P0C0L4 | C4A | More | | | Acrivastine | hsa04612 | Antigen processing and presentation | 3.23E-03 | 7 | P13765, P48382, P26715, P26717, Q13241, P01732, P01375 | HLA-DOB, RFX5, KLRC1, KLRC2, KLRD1, CD8A, TNF | More | | | Acrivastine | hsa04613 | Neutrophil extracellular trap formation | 7.55E-06 | 19 | P11215, P05164, P08246, Q9UM07, Q13547, P04908, Q93077, P62807, Q16778, O60814, P68431, P20160, P08311, P49913, O75015, P21730, P21462, O43315, Q16539 | ITGAM, MPO, ELA2, PADI4, HDAC1, H2AC4; H2AC8, HIST1H2AC, HIST1H2BC, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, AZU1, CTSG, CAMP, FCGR3B, C5AR1, FPR1, AQP9, MAPK14 | More | | | Acrivastine | hsa04640 | Hematopoietic cell lineage | 1.37E-02 | 7 | P14778, P27930, P11215, P25063, P07766, P01732, P09564 | IL1R1, IL1R2, ITGAM, CD24, CD3E, CD8A, CD7 | More | | | Acrivastine | hsa04650 | Natural killer cell mediated cytotoxicity | 2.08E-06 | 15 | P16298, P50591, P19174, P01375, P06239, O60880, P20963, P42338, Q02750, Q13241, P26718, O14931, O75015, P26717, P26715 | PPP3CB, TNFSF10, PLCG1, TNF, LCK, SH2D1A, CD247, PIK3CB, MAP2K1, KLRD1, KLRK1, NCR3, FCGR3B, KLRC2, KLRC1 | More | | | Acrivastine | hsa04658 | Th1 and Th2 cell differentiation | 2.21E-04 | 8 | Q04759, P07766, P20963, P19174, P06239, Q9UL17, P14784, Q13761 | PRKCQ, CD3E, CD247, PLCG1, LCK, TBX21, IL2RB, RUNX3 | More | | | Acrivastine | hsa04659 | Th17 cell differentiation | 1.89E-04 | 11 | Q04759, P19174, P06239, P42224, P14784, P14778, P40189, Q9UL17, P08238, P07766, P20963 | PRKCQ, PLCG1, LCK, STAT1, IL2RB, IL1R1, IL6ST, TBX21, HSP90AB1, CD3E, CD247 | More | | | Acrivastine | hsa04660 | T cell receptor signaling pathway | 3.37E-03 | 8 | Q04759, P42338, P19174, P07766, P20963, P01732, Q13191, P06239 | PRKCQ, PIK3CB, PLCG1, CD3E, CD247, CD8A, CBLB, LCK | More | | | Acrivastine | hsa04666 | Fc gamma R-mediated phagocytosis | 3.08E-02 | 3 | P42338, P23528, P14598 | PIK3CB, CFL1, NCF1 | More | | | Acrivastine | hsa04710 | Circadian rhythm | 1.67E-02 | 2 | Q16526, Q9Y478 | CRY1, PRKAB1 | More | | | Acrivastine | hsa04714 | Thermogenesis | 5.21E-03 | 4 | Q16539, P33121, Q16718, O14521 | MAPK14, ACSL1, NDUFA5, SDHD | More | | | Acrivastine | hsa04720 | Long-term potentiation | 1.38E-02 | 3 | P16298, P51812, Q02750 | PPP3CB, RPS6KA3, MAP2K1 | More | | | Acrivastine | hsa04722 | Neurotrophin signaling pathway | 3.27E-02 | 3 | P49841, O43524, P48023 | GSK3B, FOXO3, FASLG | More | | | Acrivastine | hsa04725 | Cholinergic synapse | 3.74E-02 | 3 | P22694, Q14643, P10415 | PRKACB, ITPR1, BCL2 | More | | | Acrivastine | hsa04750 | Inflammatory mediator regulation of TRP channels | 7.24E-03 | 5 | P14778, P19174, P42338, P24723, Q04759 | IL1R1, PLCG1, PIK3CB, PRKCH, PRKCQ | More | | | Acrivastine | hsa04913 | Ovarian steroidogenesis | 2.72E-02 | 2 | P42330, P22694 | AKR1C3, PRKACB | More | | | Acrivastine | hsa04914 | Progesterone-mediated oocyte maturation | 2.97E-03 | 6 | Q17RY0, P42338, Q13370, P08238, P51812, Q02750 | CPEB4, PIK3CB, PDE3B, HSP90AB1, RPS6KA3, MAP2K1 | More | | | Acrivastine | hsa04920 | Adipocytokine signaling pathway | 4.31E-02 | 2 | Q9Y478, Q96RR4 | PRKAB1, CAMKK2 | More | | | Acrivastine | hsa04923 | Regulation of lipolysis in adipocytes | 2.24E-02 | 3 | P07550, P42338, Q9Y4H2 | ADRB2, PIK3CB, IRS2 | More | | | Acrivastine | hsa04924 | Renin secretion | 2.65E-04 | 5 | P22694, P07550, Q14643, Q13370, P0DP23 | PRKACB, ADRB2, ITPR1, PDE3B, CALM1 | More | | | Acrivastine | hsa04927 | Cortisol synthesis and secretion | 2.72E-02 | 2 | Q14643, P22694 | ITPR1, PRKACB | More | | | Acrivastine | hsa04928 | Parathyroid hormone synthesis, secretion and action | 1.02E-02 | 4 | Q14643, P22694, P23771, P10415 | ITPR1, PRKACB, GATA3, BCL2 | More | | | Acrivastine | hsa04932 | Non-alcoholic fatty liver disease | 2.44E-03 | 5 | P01375, P49841, P48023, Q16718, O14521 | TNF, GSK3B, FASLG, NDUFA5, SDHD | More | | | Acrivastine | hsa04934 | Cushing syndrome | 4.74E-02 | 3 | Q14643, P22694, P04628 | ITPR1, PRKACB, WNT1 | More | | | Acrivastine | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | | Acrivastine | hsa04950 | Maturity onset diabetes of the young | 2.03E-02 | 1 | P35557 | GCK | More | | | Acrivastine | hsa04970 | Salivary secretion | 2.11E-02 | 3 | P07550, P22694, Q14643 | ADRB2, PRKACB, ITPR1 | More | | | Acrivastine | hsa04973 | Carbohydrate digestion and absorption | 1.29E-02 | 2 | O43451, P42338 | MGAM, PIK3CB | More | | | Acrivastine | hsa04976 | Bile secretion | 3.32E-02 | 2 | O43315, P08183 | AQP9, ABCB1 | More | | | Acrivastine | hsa05020 | Prion disease | 3.80E-02 | 4 | Q16718, O14521, P49841, Q16539 | NDUFA5, SDHD, GSK3B, MAPK14 | More | | | Acrivastine | hsa05022 | Pathways of neurodegeneration - multiple diseases | 1.24E-02 | 6 | P49841, Q16718, O14521, Q13561, Q16539, Q08752 | GSK3B, NDUFA5, SDHD, DCTN2, MAPK14, PPID | More | | | Acrivastine | hsa05034 | Alcoholism | 3.90E-04 | 4 | Q93077, P62807, O60814, P68431 | HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | | Acrivastine | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 2.78E-03 | 5 | P09341, P19875, P19174, P25024, P25025 | CXCL1, CXCL2, PLCG1, CXCR1, CXCR2 | More | | | Acrivastine | hsa05133 | Pertussis | 4.94E-02 | 1 | P0C0L4 | C4A | More | | | Acrivastine | hsa05134 | Legionellosis | 1.29E-02 | 4 | P11215, P11142, P09341, P19875 | ITGAM, HSPA8, CXCL1, CXCL2 | More | | | Acrivastine | hsa05140 | Leishmaniasis | 1.09E-02 | 4 | P14598, P42224, O60603, Q15080 | NCF1, STAT1, TLR2, NCF4 | More | | | Acrivastine | hsa05143 | African trypanosomiasis | 2.72E-02 | 2 | P01375, P48023 | TNF, FASLG | More | | | Acrivastine | hsa05146 | Amoebiasis | 1.36E-05 | 11 | P09341, P19875, P14778, P27930, P01375, P42338, P11215, P05089, P22694, P12814, P08311 | CXCL1, CXCL2, IL1R1, IL1R2, TNF, PIK3CB, ITGAM, ARG1, PRKACB, ACTN1, CTSG | More | | | Acrivastine | hsa05150 | Staphylococcus aureus infection | 1.67E-02 | 5 | P21730, P21462, O75015, P12838, P49913 | C5AR1, FPR1, FCGR3B, DEFA4, CAMP | More | | | Acrivastine | hsa05152 | Tuberculosis | 1.95E-02 | 5 | P48382, P10415, P13765, Q9UDY8, P51617 | RFX5, BCL2, HLA-DOB, MALT1, IRAK1 | More | | | Acrivastine | hsa05160 | Hepatitis C | 1.27E-02 | 4 | P60033, P49841, P01375, P48023 | CD81, GSK3B, TNF, FASLG | More | | | Acrivastine | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 1.94E-02 | 4 | P62879, P16298, Q02750, P0CG47 | GNB2, PPP3CB, MAP2K1, UBB | More | | | Acrivastine | hsa05168 | Herpes simplex virus 1 infection | 1.15E-02 | 8 | P42224, Q07955, Q01130, Q13243, P42338, Q13398, Q03923, Q9UDV6 | STAT1, SFRS1, SFRS2, SFRS5, PIK3CB, ZNF211, ZNF85, ZNF212 | More | | | Acrivastine | hsa05170 | Human immunodeficiency virus 1 infection | 6.02E-03 | 5 | Q02750, P62879, P16298, Q05397, P20333 | MAP2K1, GNB2, PPP3CB, PTK2, TNFRSF1B | More | | | Acrivastine | hsa05200 | Pathways in cancer | 3.92E-02 | 9 | P42338, P08238, P42224, P43246, P14923, O75293, P0DP23, P14784, P40189 | PIK3CB, HSP90AB1, STAT1, MSH2, JUP, GADD45B, CALM1, IL2RB, IL6ST | More | | | Acrivastine | hsa05202 | Transcriptional misregulation in cancer | 3.11E-03 | 12 | Q13315, P14780, P27930, P14923, Q15744, Q16548, P05164, P12838, P08246, Q9C0K0, Q13547, P24522 | ATM, MMP9, IL1R2, JUP, CEBPE, BCL2A1, MPO, DEFA4, ELA2, BCL11B, HDAC1, GADD45A | More | | | Acrivastine | hsa05203 | Viral carcinogenesis | 2.93E-03 | 3 | Q15283, P62807, O60814 | RASA2, HIST1H2BC, H2BC12 | More | | | Acrivastine | hsa05204 | Chemical carcinogenesis | 1.48E-02 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | | Acrivastine | hsa05212 | Pancreatic cancer | 1.72E-02 | 3 | P42338, P42224, O75293 | PIK3CB, STAT1, GADD45B | More | | | Acrivastine | hsa05213 | Endometrial cancer | 3.79E-02 | 2 | O15169, Q02750 | AXIN1, MAP2K1 | More | | | Acrivastine | hsa05214 | Glioma | 1.72E-02 | 3 | P0DP23, P42338, O75293 | CALM1, PIK3CB, GADD45B | More | | | Acrivastine | hsa05221 | Acute myeloid leukemia | 3.29E-02 | 3 | P14923, Q15744, P05164 | JUP, CEBPE, MPO | More | | | Acrivastine | hsa05226 | Gastric cancer | 3.79E-02 | 2 | Q02750, O15169 | MAP2K1, AXIN1 | More | | | Acrivastine | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 8.27E-03 | 6 | P42338, P19174, P07766, P20963, P06239, Q04759 | PIK3CB, PLCG1, CD3E, CD247, LCK, PRKCQ | More | | | Acrivastine | hsa05310 | Asthma | 3.01E-02 | 2 | P13765, P12724 | HLA-DOB, RNASE3 | More | | | Acrivastine | hsa05321 | Inflammatory bowel disease | 1.87E-02 | 4 | P01375, Q14765, Q9UL17, P23771 | TNF, STAT4, TBX21, GATA3 | More | | | Acrivastine | hsa05322 | Systemic lupus erythematosus | 1.49E-05 | 5 | P09871, Q93077, P62807, O60814, P68431 | C1S, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | | Acrivastine | hsa05323 | Rheumatoid arthritis | 2.00E-02 | 3 | Q13488, P10747, O60603 | TCIRG1, CD28, TLR2 | More | | | Acrivastine | hsa05330 | Allograft rejection | 2.72E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | | Acrivastine | hsa05332 | Graft-versus-host disease | 4.73E-03 | 4 | P48023, P01375, P26715, Q13241 | FASLG, TNF, KLRC1, KLRD1 | More | | | Acrivastine | hsa05415 | Diabetic cardiomyopathy | 1.28E-02 | 4 | Q16718, O14521, Q16539, P49841 | NDUFA5, SDHD, MAPK14, GSK3B | More | | | Acrivastine | hsa05418 | Fluid shear stress and atherosclerosis | 3.73E-02 | 4 | P42338, P14598, P0DP23, P08238 | PIK3CB, NCF1, CALM1, HSP90AB1 | More | |
|
